K Asaoka1, M Tada, Y Sawamura, J Ikeda, H Abe. 1. Department of Neurosurgery, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan.
Abstract
OBJECT: Recombinant adenovirus is used as a competent vector in a wide spectrum of cancer gene therapies because of its high efficiency in gene delivery. To study the feasibility of gene therapy in malignant gliomas, the authors examined the antiproliferative effect of the adenovirally transduced wild-type p53 tumor suppressor gene by using 15 different high-grade glioma cell lines. METHODS: Although growth suppression in association with a high adenoviral p53 transduction efficiency was seen in five of 15 cell lines, it was not observed in the remaining 10 cell lines. To clarify the underlying mechanism, we examined the expression levels of the Coxsackievirus and adenovirus receptor (CAR), which is the primary receptor for adenovirus, and of the integrins alpha vbeta3 and alpha vbeta5, which promote adenoviral internalization. The expression level of the CAR gene showed a close correlation to adenoviral gene transduction efficiency in the tested cell lines, whereas the expression levels of the integrins did not. The CAR expression was decreased by wild-type p53 transduction in U251MG cells harboring mutant p53 and increased by antisense inhibition of p53 in LN443 cells with endogenous wild-type p53. CONCLUSIONS: The results of this study indicate that CAR expression is a critical determinant of transduction efficiencies in adenovirus-based gene therapy for human malignant gliomas.
OBJECT: Recombinant adenovirus is used as a competent vector in a wide spectrum of cancer gene therapies because of its high efficiency in gene delivery. To study the feasibility of gene therapy in malignant gliomas, the authors examined the antiproliferative effect of the adenovirally transduced wild-type p53tumor suppressor gene by using 15 different high-grade glioma cell lines. METHODS: Although growth suppression in association with a high adenoviral p53 transduction efficiency was seen in five of 15 cell lines, it was not observed in the remaining 10 cell lines. To clarify the underlying mechanism, we examined the expression levels of the Coxsackievirus and adenovirus receptor (CAR), which is the primary receptor for adenovirus, and of the integrins alpha vbeta3 and alpha vbeta5, which promote adenoviral internalization. The expression level of the CAR gene showed a close correlation to adenoviral gene transduction efficiency in the tested cell lines, whereas the expression levels of the integrins did not. The CAR expression was decreased by wild-type p53 transduction in U251MG cells harboring mutant p53 and increased by antisense inhibition of p53 in LN443 cells with endogenous wild-type p53. CONCLUSIONS: The results of this study indicate that CAR expression is a critical determinant of transduction efficiencies in adenovirus-based gene therapy for humanmalignant gliomas.
Authors: Marianela Candolfi; James F Curtin; Wei-Dong Xiong; Kurt M Kroeger; Chunyan Liu; Altan Rentsendorj; Hasmik Agadjanian; Lali Medina-Kauwe; Donna Palmer; Philip Ng; Pedro R Lowenstein; Maria G Castro Journal: Mol Ther Date: 2006-06-23 Impact factor: 11.454
Authors: J Ikeda; M Tada; N Ishii; H Saya; K Tsuchiya; K Okaichi; K Mishima; Y Sawamura; G Fulci; T J Liu; E G Van Meir Journal: Int J Cancer Date: 2001-10-01 Impact factor: 7.396
Authors: Michael D Blough; Desiree C Beauchamp; Morgan R Westgate; John J Kelly; J Gregory Cairncross Journal: J Neurooncol Date: 2010-07-01 Impact factor: 4.130
Authors: Melinda K Merrill; Guenter Bernhardt; John H Sampson; Carol J Wikstrand; Darell D Bigner; Matthias Gromeier Journal: Neuro Oncol Date: 2004-07 Impact factor: 12.300
Authors: E M Lee; S H Hong; Y J Lee; Y H Kang; K C Choi; S H Choi; I H Kim; S J Lim Journal: J Cancer Res Clin Oncol Date: 2003-12-16 Impact factor: 4.553